Given that left atrial strain (LAS) parameters have been established as valuable predictors of AF in various patient cohorts [100], these findings suggest a hypothesis: SGLT2 inhibitors may mitigate AF and AFL by reducing myocardial remodelling through their influence on left atrial filling pressure and left ventricular end-diastolic pressure (LVEDP) [100]. Here, SLC5A2 is linked to atrial fibrillation.